ISTH Guidelines recommend CABLIVI (caplacizumab-yhdp)*

The ISTH TTP Guidelines recommend CABLIVI*

in combination with PEX and immunosuppressive therapy in adults with acute acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP)—for initial and relapse events1,2

Warning symbol

aTTP/iTTP presentation varies

CABLIVI (caplacizumab-yhdp) dots

The first of its kind

Hand holding gear

CABLIVI Patient Solutions: From hospital to home

*A conditional recommendation defined as desirable effects of the recommendation probably outweighing the undesirable effects. Assumes timely access to ADAMTS13 testing and clinical diagnosis based on high likelihood of aTTP/iTTP. In de novo patients where no reasonable access to ADAMTS13 activity testing is available, the Guidelines do not recommend CABLIVI; however, treatment of a patient previously diagnosed with aTTP/iTTP could be safely undertaken on clinical grounds without the need for a confirmatory ADAMTS13 test.1

ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 13; ISTH=International Society on Thrombosis and Haemostasis; MAHA=microangiopathic hemolytic anemia; MOA=mechanism of action; PEX=plasma exchange; TTP=thrombotic thrombocytopenic purpura.